CELGENE CORP's ticker is CELG and the CUSIP is 151020104.
About CELGENE CORP
Celgene Corp is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative therapies for the treatment of cancer and other serious diseases. The company is headquartered in Summit, New Jersey, and has operations in more than 60 countries worldwide.
Celgene's portfolio of products includes some of the most innovative and effective therapies for the treatment of cancer, including Revlimid, Pomalyst, and Abraxane. These drugs have been approved by regulatory agencies around the world and have helped millions of patients to live longer, healthier lives.
In addition to its core business of developing and commercializing innovative therapies, Celgene is also committed to advancing the science of medicine through research and development. The company invests heavily in research and development, with a focus on developing new treatments for cancer and other serious diseases.
Despite its success, Celgene faces a number of challenges in the years ahead. The company must continue to innovate and develop new therapies to stay ahead of the competition, while also navigating a complex regulatory environment and managing the risks associated with drug development.
Overall, Celgene is a company with a strong track record of success and a bright future ahead. With its focus on innovation, research, and development, the company is well-positioned to continue to deliver value to patients, investors, and society as a whole.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,798,000 | +19.3% | 12,333 | +6.3% | 0.42% | +17.8% |
| Q2 2017 | $1,507,000 | +9.4% | 11,603 | +4.8% | 0.36% | +9.5% |
| Q1 2017 | $1,377,000 | +5.8% | 11,068 | -1.5% | 0.33% | +1.5% |
| Q4 2016 | $1,301,000 | +6.3% | 11,239 | -4.1% | 0.32% | +6.2% |
| Q3 2016 | $1,224,000 | +59.4% | 11,714 | +50.5% | 0.30% | +60.8% |
| Q2 2016 | $768,000 | – | 7,785 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Birchview Capital, LP | 709,181 | $63,266,000 | 41.66% |
| OAKTOP CAPITAL MANAGEMENT II, L.P. | 2,166,359 | $193,261,000 | 40.48% |
| BOURNE LENT ASSET MANAGEMENT INC | 440,004 | $39,253,000 | 21.32% |
| Edinburgh Partners | 315,906 | $28,182,000 | 12.91% |
| Selkirk Management LLC | 270,000 | $24,087,000 | 12.36% |
| FCG ADVISORS, LLC | 343,318 | $30,627,000 | 10.58% |
| TAYLOR ASSET MANAGEMENT INC | 264,300 | $23,020,000 | 9.88% |
| BB BIOTECH AG | 3,324,298 | $296,561,000 | 8.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 205,522 | $18,335,000 | 7.15% |
| Aristotle Atlantic Partners, LLC | 173,661 | $15,492,000 | 5.59% |